FDA Panel on Peptide Drugs Includes Experts with Financial Ties to Unproven Chemical Industry
By
Associated Press
Summary
The FDA has announced participants for an upcoming meeting to reconsider the safety and effectiveness of controversial peptide drugs. The panel will include doctors and pharmacists who have financial ties to the industry of unproven peptide chemicals. This has raised concerns about conflicts of interest, especially given that Health Secretary Robert F. Kennedy Jr. has praised several popular peptide injections. The article examines the regulatory challenges and ethical questions surrounding the FDA's review process.
Source
bskyFDA Panel on Peptide Drugs Includes Experts with Financial Ties to Unproven Chemical Industrymedpagetoday.comKey quotes
· 3 pulledWhen U.S. health officials meet next month to reconsider a list of controversial peptide drugs, they will hear from a new set of voices: doctors and pharmacists with deep financial ties to the burgeoning industry of unproven chemicals.
The FDA on Monday released its list of participants for an upcoming meeting to reconsider the safety and effectiveness of several
Several popular peptide injections have been praised by Health Secretary Robert F. Kennedy Jr.
You might also wanna read
Inside the Grey Market Peptide Economy: Regulatory Gaps and Underground Pharmaceutical Infrastructure
This article investigates the parallel pharmaceutical infrastructure built around grey market peptides like BPC-157 and semaglutide. It cont
vectorculture.substack.com·5mo ago
FDA Announces Loosened Restrictions on Synthetic Peptide Use in Children
The FDA announces it has loosened restrictions on dousing children with synthetic peptides, with the commissioner stating that while the eff
The Onion·2mo ago
Study Finds 60% of DSM-5-TR Panel Members Had Undisclosed Financial Ties to Pharmaceutical Industry
A cross-sectional analysis of 92 US-based physicians who served on DSM-5-TR panels found that 60% received industry payments totaling $14.2
bmj.com·10mo ago
HHS Secretary Kennedy Calls for Deprescribing Psychiatric Medications, Sparking Debate on Overprescription
This article examines HHS Secretary Robert F. Kennedy Jr.'s call to deprescribe psychiatric medications "when clinically indicated," made at
ja.ma·3d ago
Conflicts of interest threaten integrity of GLP-1 therapy guidance, experts warn
This article discusses the risks of conflicts of interest in clinical guidance for GLP-1 receptor agonists (like Ozempic, Wegovy) used for o
bit.ly·10d ago
Conflicts of interest threaten integrity of GLP-1 therapy guidance amid rapid adoption
This article discusses the rapid uptake and commercial success of GLP-1 receptor agonists for obesity management, highlighting their clinica
bmj.com·10d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.